Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria – Is nitisinone the solution?

[1]  A. Milan,et al.  ANNALS EXPRESS: Alkaptonuria - many questions answered, further challenges beckon. , 2019, Annals of clinical biochemistry.

[2]  J. Jarvis,et al.  Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria , 2020, Journal of inherited metabolic disease.

[3]  U. Jäger,et al.  Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. , 2019, Blood reviews.

[4]  M. Merten,et al.  Efficacy of low dose nitisinone in the management of alkaptonuria. , 2019, Molecular genetics and metabolism.

[5]  J. Nine,et al.  Ochronosis Presenting as Methemoglobinemia , 2018, Journal of forensic sciences.

[6]  A. Milan,et al.  Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. , 2018, Molecular genetics and metabolism.

[7]  Stephen Wills,et al.  Fatal methemoglobinemia complicating alkaptonuria (ochronosis): a rare presentation , 2018, Forensic Science, Medicine and Pathology.

[8]  L. Ranganath,et al.  The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool , 2017, Annals of clinical biochemistry.

[9]  Annalisa Santucci,et al.  Comparative proteomics in alkaptonuria provides insights into inflammation and oxidative stress. , 2016, The international journal of biochemistry & cell biology.

[10]  L. Ranganath,et al.  Acute fatal metabolic complications in alkaptonuria , 2016, Journal of Inherited Metabolic Disease.

[11]  Annalisa Santucci,et al.  Oxidative stress and mechanisms of ochronosis in alkaptonuria. , 2015, Free radical biology & medicine.

[12]  L. Ranganath,et al.  Serum concentrations and urinary excretion of homogentisic acid and tyrosine in normal subjects , 2015, Clinical chemistry and laboratory medicine.

[13]  Andrea Zatkova,et al.  Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte , 2014, Annals of the rheumatic diseases.

[14]  G. Taylor,et al.  Fatal oxidative haemolysis and methaemoglobinaemia in a patient with alkaptonuria and acute kidney injury , 2014, Clinical kidney journal.

[15]  A. D. Lichtman,et al.  Methemoglobinemia: a review and recommendations for management. , 2014, Journal of cardiothoracic and vascular anesthesia.

[16]  Shanshan He,et al.  Evaluation of Antitrypanosomal Dihydroquinolines for Hepatotoxicity, Mutagenicity, and Methemoglobin Formation In Vitro , 2014, International journal of toxicology.

[17]  J. Grünfeld,et al.  Hemolysis: a fatal complication of alkaptonuria in a severe renal failure patient. , 2014, Clinical nephrology.

[18]  L. Ranganath,et al.  Interferences of homogentisic acid (HGA) on routine clinical chemistry assays in serum and urine and the implications for biochemical monitoring of patients with alkaptonuria. , 2014, Clinical biochemistry.

[19]  M. Karsdal,et al.  Circulating Protein Fragments of Cartilage and Connective Tissue Degradation Are Diagnostic and Prognostic Markers of Rheumatoid Arthritis and Ankylosing Spondylitis , 2013, PLoS ONE.

[20]  David C. Thompson,et al.  Biomarkers in rheumatology, now and in the future. , 2012, Rheumatology.

[21]  Annalisa Santucci,et al.  Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis , 2011, Journal of Inherited Metabolic Disease.

[22]  J. Troendle,et al.  A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. , 2011, Molecular genetics and metabolism.

[23]  L. Ranganath,et al.  Natural history of alkaptonuria revisited: analyses based on scoring systems , 2011, Journal of Inherited Metabolic Disease.

[24]  A. Zatkova,et al.  An update on molecular genetics of Alkaptonuria (AKU) , 2011, Journal of Inherited Metabolic Disease.

[25]  Annalisa Santucci,et al.  Proteomic and redox‐proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes , 2010, Journal of cellular biochemistry.

[26]  D. Braconi,et al.  Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. , 2010, Rheumatology.

[27]  B. Souweine,et al.  Hemolysis in a patient with alkaptonuria and chronic kidney failure. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  H. Shintani,et al.  Acute methemoglobinemia associated with ochronotic valvular heart disease: report of a case. , 2010, The Thoracic and cardiovascular surgeon.

[29]  M. Cappellini,et al.  Glucose-6-phosphate dehydrogenase deficiency , 2008, The Lancet.

[30]  M. Kaiser-Kupfer,et al.  Use of nitisinone in patients with alkaptonuria. , 2005, Metabolism: clinical and experimental.

[31]  William A Gahl,et al.  Natural history of alkaptonuria. , 2002, The New England journal of medicine.

[32]  R. Prayson,et al.  Dura mater involvement in ochronosis (alkaptonuria). , 2001, Archives of pathology & laboratory medicine.

[33]  M. Peñalva,et al.  The molecular basis of alkaptonuria , 1996, Nature Genetics.

[34]  J. Vondráček,et al.  [Analysis of the life span of alkaptonuric patients]. , 1985, Casopis lekaru ceskych.

[35]  M. Kamochi,et al.  A rare case of acquired methemoglobinemia associated with alkaptonuria. , 2014, Internal medicine.

[36]  J. Opitz,et al.  A fifty-year-old man with skin pigmentation, arthritis, chronic renal failure and methemoglobinemia. , 1983, American journal of medical genetics.